Trial Profile
A Prospective, Multi-centric, Randomized, Double-blind, Parallel, Saline Controlled Phase II Safety and Efficacy Study of PMZ-2010 as a Resuscitative Agent for Hypovolemic Shock to be Used Along With Standard Shock Treatment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Centhaquine (Primary)
- Indications Hypovolaemic shock
- Focus Adverse reactions
- Sponsors Pharmazz
- 10 May 2021 Results assessing safety and efficacy of centhaquine in patients with hypovolemic shock, published in the Advances in Therapy.
- 10 May 2021 According to a Pharmazz media release, results from this trial were published in the Advances in Therapy.
- 10 May 2021 Results published in the Pharmazz Media Release.